Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.
<h4>Background</h4>Palonosetron is a potent second generation 5- hydroxytryptamine-3 selective antagonist which can be administered by either intravenous (IV) or oral routes, but subcutaneous (SC) administration of palonosetron has never been studied, even though it could have useful cli...
Saved in:
| Main Authors: | Belen Sadaba, Anabel del Barrio, Miguel Angel Campanero, Jose Ramon Azanza, Almudena Gomez-Guiu, Jose Maria Lopez-Picazo, Salvador Martin Algarra, Francisco Guillén Grimá, Maria Blanco Prieto, Jose Luis Perez-Gracia, Alfonso Gurpide |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0089747&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics of Doxycycline in Alpacas After Intravenous and Subcutaneous Administration
by: José Martínez, et al.
Published: (2025-03-01) -
A Case of Possible Infusion-Related Reactions Caused by Palonosetron
by: Toru Kadono, et al.
Published: (2025-02-01) -
Optimizing Infliximab Use in Real-World Inflammatory Bowel Disease: Insights from a Population Pharmacokinetic Model Integrating Intravenous and Subcutaneous Formulations
by: Sung Hoon Jung, et al.
Published: (2025-05-01) -
Pharmacokinetic profile and in vivo anticancer efficacy of anagrelide administered subcutaneously in rodents
by: Kirsi Toivanen, et al.
Published: (2025-12-01) -
Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
by: Joo Hye Song, et al.
Published: (2025-05-01)